Loading...
Ons wil graag hê dat jy deel word van ons gemeenskap. Sluit aan by ons Discord om met ons en ander lede te skakel!
- Ticker
- BHVN
- Price
- 14.46
- Stock movement up
- +0.07 (0.49%)
- Company name
- Biohaven Pharmaceutical Holding Co Ltd
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markkapitalisasie
- 1.53B
- Ondernemingswaarde
- 1.64B
- Prys/Verkope
- -
- Prys/Boek
- 4.84
- Dividendopbrengs
- -
- Dividendgroei
- -
- Groei jare
- -
- FCF uitbetaling
- -
- Agterlopende P/E
- -
- Volgende P/E
- -
- PEG
- -
- EPS groei
- -1.39%
- 1 jaar opbrengs
- -56.17%
- 3 jaar opbrengs
- -53.28%
- 5 jaar opbrengs
- -22.12%
- 10 jaar opbrengs
- -
Laaste opgedateer: 2025-08-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDE
BHVN betaal nie dividende nie of geen data is ontvang nie
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
WAARDERING
Waarderingsverhoudings
Loading...
Waarderingsverhoudings gegewens
| Agterlopende P/E | - |
| Prys tot OCF | - |
| Prys tot FCF | - |
| Prys tot EBITDA | - |
| EV tot EBITDA | - |
Waardering (Verkope/Boekwaarde)
Loading...
Waardering (Verkope/Boekwaarde) gegewens
| Prys tot verkope | - |
| Prys tot Boekwaarde | 4.84 |
| EV tot verkope | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANSIËLE
Per aandeel
Loading...
Per aandeel gegewens
| Huidige aandeeltelling | 105.79M |
| EPS (TTM) | -8.52 |
| FCF per aandeel (TTM) | -5.63 |
Inkomstestaat
Loading...
Inkomstestaat gegewens
| Inkomste (TTM) | 0.00 |
| Bruto wins (TTM) | -2.87M |
| Bedryfsinkomste (TTM) | -848.89M |
| Netto inkomste (TTM) | -804.34M |
| EPS (TTM) | -8.52 |
| EPS (1j vorentoe) | -5.15 |
Marges
Loading...
Marges gegewens
| Bruto marge (TTM) | - |
| Bedryfsmarge (TTM) | - |
| Winsgrens (TTM) | - |
Balansstaat
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Balansstaat gegewens
| Kontant | 84.39M |
| Netto debiteure | 5.32M |
| Totale bedryfsbates | 440.50M |
| Klandisiewaarde | 1.39M |
| Ontasbare bates | 18.40M |
| Eiendom, aanleg en toerusting | 58.38M |
| Totale bates | 510.52M |
| Rekeninge betaalbaar | 19.74M |
| Kort/huidige langtermynskuld | 28.99M |
| Totale bedryfslaste | 152.29M |
| Totale laste | 194.52M |
| Aandeelhouersbelang | 316.01M |
| Netto tasbare bates | 0.00 |
Kontantvloei
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Kontantvloei gegewens
| Bedryfskontantvloei (TTM) | -526.59M |
| Kapitale uitgawes (TTM) | 4.47M |
| Vrye kontantvloei (TTM) | -531.06M |
| Dividende betaal (TTM) | 0.00 |
Finansiële opbrengste
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Finansiële opbrengste gegewens
| Opbrengs op ekwiteit | -254.53% |
| Opbrengs op bates | -157.55% |
| Opbrengs op belegde kapitaal | -251.60% |
| Kontant opbrengs op belegde kapitaal | -166.12% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
AANDELE INLIGTING
Aandele grafiek
Loading...
Aandele prys data
| Open | 14.48 |
| Daaglikse hoog | 14.63 |
| Daaglikse laag | 13.87 |
| Daaglikse volume | 2.79M |
| Hoogtepunt van alle tye | 149.26 |
| 1j analiseraaming | 47.14 |
| Beta | 3.50 |
| EPS (TTM) | -8.52 |
| Dividend per aandeel | - |
| Ex-dividend datum | - |
| Volgende verdienste datum | 18 Nov 2025 |
Afwaartse potensiaal
Loading...
Afwaartse potensiaal gegewens
| BHVN | S&P500 | |
| Huidige prysdaling vanaf die hoogste punt van alle tye | -90.31% | -3.04% |
| Hoogste prysdaling | -95.78% | -56.47% |
| Datum van hoogste daling | 30 Sep 2022 | 9 Mar 2009 |
| Gemiddelde daling vanaf hoogtepunt | -37.91% | -11.04% |
| Gemiddelde tyd tot nuwe hoogtepunt | 24 days | 12 days |
| Maksimum tyd tot nuwe hoogtepunt | 688 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
MAATSKAPPY BESONDERHEDE
Markkapitalisasie
1.53B
Markkapitalisasie kategorie
Small-cap
Beskrywing
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and c
Werknemers
256
Webwerf
Beleggerverhoudings
-
SEC lêers
CEO
Vlad Coric
Land
USA
Stad
New Haven
Aandele tipe
Common stock
CCC status
-
Dividendfrekwensie
-
GEBEURE EN AANBIEDINGS
GebeureAanbiedings
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VERSTAAN DIE BESIGHEID
Loading...
MAATSKAPPY NUUS
Seeking AlphaPersvrystellings
iO Charts is a Seeking Alpha partnerVolgende bladsy